Home / Biotechnology / Preterm Bi

Preterm Birth And PROM Testing Market By Test Type (Pelvic Exam, Ferning Test, Nitrazine Test, Pooling Test, Ultrasound Test, Uterine Monitoring Test, Biomarkers) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Industry Outlook

The preterm birth and PROM testing market is set to reach from US$ 996.3 Mn in 2017 to US$ 1,201.2 Mn by 2026 representing slow growth at a compounded annual growth rate (CAGR) of 2.1% during the forecast period from 2018 to 2026. As per the research findings of the World Health Organization (WHO), 15 million babies are born annually before the completion of 37 weeks of normal pregnancy. As a result, approximately 1 million children die annually due to complications associated with preterm births.

Excellent diagnostic accuracy and sensitivity will increase the popularity of biomarkers as PROM testing kits.

Physicians investigate preliminary symptoms such as vaginal bleeding, vaginal discharge, pelvic pressure, etc., to confirm preterm birth complications. Pelvic examination is the first line of diagnostic approach, which is performed several times to study the contraction and changes of the cervix. If the cervix begins to soften, dilate and become thin before 37 weeks of pregnancy, the patient is diagnosed with preterm labor. Biomarkers such as the Alpha-fetoprotein test (AFT), insulin-like growth factor binding protein-1 (IGFBP-1), placental alpha macroglobulin-1 (PAMG-1), etc., are gaining tremendous attention in the last decade. Excellent diagnostic accuracy and sensitivity increase the popularity of biomarkers as PROM testing kits.

"Rising incidence of premature births and increasing maternal health awareness drive the market growth in North America region."

In the present scenario, North America is leading the regional segment for the preterm birth and PROM testing market with a share of 36%. Annually 3.9 million babies are born in North America, of which 12.0% are born prematurely. The rising incidence of premature births and increasing maternal health awareness drive market growth in the North American region. The existence of major players such as Abbott Laboratories, CooperSurgical, Inc., Qiagen, Inc., Hologic, Inc., etc., further propels the market growth in the North American region. Europe is the second largest market, with a share of 28% on account of the supportive regulatory environment provided by the European Medical Agency (EMA) for PROM testing kits and the establishment of well-developed healthcare infrastructure. The Asia Pacific currently holds a 15% market share and will be showcasing rapid growth in the near future due to increasing pregnancy complications and proactive government initiatives to provide optimum maternal care.

Historical & Forecast Period

This research report presents the analysis of each segment from 2016 to 2026, considering 2017 as the base year for the research. In addition, compounded annual growth rate (CAGR) for each respective segment is calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

The market is segmented by test type and by geography. 


  •  Research Period   2017-2027  
  •  The base Year 2018  
  •  Forecast Period   2019-2027  
  •  Historical Year   2017  
  •  Unit   USD Million  

Segmentation  By Test Type (2016–2026; US$ Mn)

  • Pelvic Exam
  • Ferning Test
  • Nitrazine Test
  • Pooling Test
  • Ultrasound Test
  • Uterine Monitoring Test
  • Biomarkers

 Geography Segment (2016–2026; US$ Mn)

  • North America (U.S., Canada)
  • Europe (U.K., Germany, Rest of Europe)
  • Asia Pacific (China, Japan, Rest of APAC)
  • Latin America (Brazil, Mexico, Rest of Latin America)
  • the Middle East and Africa (GCC, Rest of the Middle East and Africa)

Biopharmaceutical companies specializing in manufacturing preterm birth and PROM testing kits are Abbott Laboratories, Inc., Biosynex, Clinical Innovations, LLC, CooperSurgical, Inc., Hologic, Inc., I.Q. Medixbiochemica, NX Prenatal, Inc., Qiagen N.V., and Sera Prognostics, Inc.

Frequently Asked Questions:

The market for Preterm Birth And PROM Testing is expected to reach US$ 1,201.2 Mn by 2026.

The Preterm Birth And PROM Testing Market is expected to see significant CAGR growth over the coming years, at 2.1%.

The report is forecasted from 2017-2026.

The base year of this report is 2021.

Abbott Laboratories, Inc., Business Description, Financial Information (Subject to data availability), Product Portfolio, News Coverage are some of the major players in the global market.

Choose License Type
Budget Buying
Executive Summary - Brief Global Market Size - Current & Forecast
Regional Market Size - North America
Country Market Size - US
Company Profile – 1
Trusted By
Published Date:  Mar 2019
Category:  Biotechnology
Report ID:   59644
Report Format:   PDF
Pages:   120
Rating:    4.2 (69)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support